The Efficacy of Current Prognostic Models in Predicting Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure

被引：0
|
作者：
Nazha, Aziz [1 ]
Komrokji, Rami S. [2 ]
Garcia-Manero, Guillermo [3 ]
Barnard, John [1 ]
Zimmerman, Cassie [1 ]
Najla, Al Ali [4 ]
Roboz, Gail J. [5 ]
Steensma, David P. [6 ]
DeZern, Amy E. [7 ]
Jabbour, Elias [3 ]
Lee, Sangmin [8 ]
Greenberg, Molly D. [9 ]
List, Alan F. [4 ]
Kantarjian, Hagop M. [3 ]
Maciejewski, Jaroslaw P. [1 ]
Sekeres, Mikkael A. [1 ]
机构：
[1] Cleveland Clin, Cleveland, OH 44106 USA
[2] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA
[3] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[4] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[5] New York Presbyterian Hosp, Weill Cornell Med Coll, New York, NY USA
[6] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
[7] Johns Hopkins Univ, Baltimore, MD USA
[8] Weill Cornell New York Presbyterian Hosp, New York, NY USA
[9] Weill Cornell Med Coll, New York, NY USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure
    Nazha, Aziz
    Komrokji, Rami S.
    Garcia-Manero, Guillermo
    Barnard, John
    Roboz, Gail J.
    Steensma, David P.
    DeZern, Amy E.
    Zell, Katrina
    Zimmerman, Cassie
    Al Ali, Najla
    Jabbour, Elias
    Greenberg, Molly D.
    Kantarjian, Hagop M.
    Maciejewski, Jaroslaw P.
    List, Alan F.
    Sekeres, Mikkael A.
    HAEMATOLOGICA, 2016, 101 (06) : E224 - E227
  • [2] A Novel Model to Predict Outcome of Patients with Myelodysplastic Syndromes (MDS) at the Time of Hypomethylating Agent Failure
    Nazha, Aziz
    Komrokji, Rami S.
    Garcia-Manero, Guillermo
    Barnard, John
    Zell, Katrina
    Zimmerman, Cassie
    Al Ali, Najla H.
    Roboz, Gail J.
    Steensma, David P.
    DeZern, Amy E.
    Padron, Eric
    Jabbour, Elias J.
    Greenberg, Molly Dara
    List, Alan F.
    Kantarjian, Hagop M.
    Maciejewski, Jaroslaw P.
    Sekeres, Mikkael A.
    BLOOD, 2015, 126 (23)
  • [3] Prognostic models in predicting outcomes in myelodysplastic syndromes after hypomethylating agent failure
    Patel, Sagar S.
    Sekeres, Mikkael A.
    Nazha, Aziz
    LEUKEMIA & LYMPHOMA, 2017, 58 (11) : 2532 - 2539
  • [4] Clinicopathologic Predictors of Hypomethylating Agent Failure in Patients with Myelodysplastic Syndromes
    Chien, Kelly S.
    Urrutia, Samuel
    Li, Ziyi
    Kanagal-Shamanna, Rashmi
    Abdelhakeem, Ahmed
    Abuasab, Tareq
    Almanza, Emmanuel
    Gener-Ricos, Georgina
    Bataller, Alex
    Bazinet, Alexandre
    Montalban-Bravo, Guillermo
    Short, Nicholas J.
    Jabbour, Elias
    Kadia, Tapan M.
    Ravandi, Farhad
    Borthakur, Gautam
    Hammond, Danielle E.
    Swaminathan, Mahesh
    Sasaki, Koji
    Dong, Xiao Qin
    Pierce, Sherry
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2023, 142
  • [5] Disease Characteristics and Outcomes of Hypomethylating Agent Failure in Patients With Myelodysplastic Syndromes
    Chien, Kelly
    Kim, Kunhwa
    Li, Ziyi
    Shamanna, Rashmi Kanagal
    Ong, Faustine
    Bravo, Guillermo Montalban
    Kadia, Tapan
    Jabbour, Elias
    Pemmaraju, Naveen
    Hammond, Danielle
    Short, Nicholas
    Ravandi, Farhad
    Alvarado, Yesid
    Pierce, Sherry
    Dong, Xiao Qin
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S311 - S311
  • [6] Treatment options for patients with myelodysplastic syndromes after hypomethylating agent failure
    Carraway, Hetty E.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2016, : 470 - 477
  • [7] The Prognostic Utility of the Current Risk Models in Predicting Outcomes of Patients (pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agents (HMA)
    Zeidan, Amer M.
    Sekeres, Mikkael A.
    Garcia-Manero, Guillermo
    Barnard, John
    Al Ali, Najla H.
    Zimmerman, Cassie
    Roboz, Gail J.
    Steensma, David P.
    DeZern, Amy E.
    Jabbour, Elias
    Kantarjian, Hagop
    Zell, Katrina
    Wang, Quiqing
    Gore, Steven D.
    Nazha, Aziz
    Maciejewski, Jaroslaw P.
    List, Alan F.
    Komrokji, Rami S.
    BLOOD, 2014, 124 (21)
  • [8] Phase II study of the clinical efficacy and safety of tosedostat in patients with myelodysplastic syndromes (MDS) after failure of hypomethylating agent-based therapy
    Lee, Sangmin
    Desai, Pinkal
    Edirisinghe, Bianca
    Pianello, Samantha
    Curcio, Tania
    Samuel, Michael
    Ritchie, Ellen K.
    Roboz, Gail J.
    LEUKEMIA & LYMPHOMA, 2021, 62 (02) : 498 - 500
  • [9] A PHASE I TRIAL OF IPILIMUMAB (IPI) IN PATIENTS (PTS) WITH MYELODYSPLASTIC SYNDROMES (MDS) AFTER HYPOMETHYLATING AGENT (HMAS) FAILURE
    Zeidan, A.
    Knaus, H.
    Robinson, T.
    Zeidner, J.
    Blackford, A.
    Duffield, A.
    Rizzieri, D.
    Frattini, M.
    Levy, M. Y.
    Schroeder, M.
    Ferguson, A.
    Sheldon, K.
    Dezern, A.
    Gojo, I.
    Gore, S.
    Streicher, H.
    Luznik, L.
    Smith, B. D.
    LEUKEMIA RESEARCH, 2017, 55 : S43 - S43
  • [10] Cost Effectiveness of Treatments after Failure of a First-Line Hypomethylating Agent in Myelodysplastic Syndromes (MDS)
    Cogle, Christopher R.
    Mukherjee, Sudipto
    Lawrence, Moira E.
    McKearn, Thomas J.
    Percy, Rita
    Petrone, Michael E.
    Megaffin, Scott
    Anene, Ayanna M.
    Ortendahl, Jesse
    Romanus, Dorothy
    Bentley, Tanya G. K.
    BLOOD, 2014, 124 (21)
12345